Q-omics provides the consensus-scored RAB30-DT profile across patient tissues and cancer cell-line models. RAB30-DT expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RAB30-DT is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, RAB30-DT RNA expression shows 19,597 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where RAB30-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB30-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB30-DT survival associations across molecular data types. RAB30-DT RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB30-DT RNA expression–survival associations across cancer types. High RAB30-DT expression shows unfavorable associations in ACC, KICH and LIHC, but favorable associations in LUSC, KIRC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RAB30-DT RNA expression.
This table summarizes RAB30-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RAB30-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB30-DT shows lower tumor expression in KICH and THCA and higher tumor expression in LIHC, HNSC, LUSC and CHOL. The KICH box plot shows higher RAB30-DT RNA expression in normal versus tumor tissue (log2 FC = −1.140, t-test p < 0.001).
This table shows molecular features associated with RAB30-DT in patient tissues and cancer cell lines. In patient samples, RAB30-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
